Research ArticleArticle
Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study
Marie Skougaard, Tanja Schjødt Jørgensen, Signe Rifbjerg-Madsen, Laura C. Coates, Alexander Egeberg, Kirstine Amris, Lene Dreyer, Pil Højgaard, Jørgen Guldberg-Møller, Joseph F. Merola, Peder Frederiksen, Henrik Gudbergsen and Lars Erik Kristensen
The Journal of Rheumatology July 2019, jrheum.181412; DOI: https://doi.org/10.3899/jrheum.181412
Marie Skougaard
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Tanja Schjødt Jørgensen
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Signe Rifbjerg-Madsen
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Laura C. Coates
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Alexander Egeberg
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Kirstine Amris
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Lene Dreyer
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Pil Højgaard
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Jørgen Guldberg-Møller
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Joseph F. Merola
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Peder Frederiksen
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Henrik Gudbergsen
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Lars Erik Kristensen
From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk. Accepted for publication June 27, 2019.
Article Information
jrheum.181412
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 15, 2019.
Article Versions
- Latest version (July 15, 2019 - 04:00).
- You are currently viewing a Latest version of this article (December 15, 2019 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2019 The Journal of Rheumatology
Author Information
- Marie Skougaard,
- Tanja Schjødt Jørgensen,
- Signe Rifbjerg-Madsen,
- Laura C. Coates,
- Alexander Egeberg,
- Kirstine Amris,
- Lene Dreyer,
- Pil Højgaard,
- Jørgen Guldberg-Møller,
- Joseph F. Merola,
- Peder Frederiksen,
- Henrik Gudbergsen and
- Lars Erik Kristensen
- From The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev, Gentofte; departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg; The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup; the Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev, Gentofte, Denmark; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
This work was supported by a core grant from the Oak Foundation [OCAY-13-309]. The research was supported by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). L.C. Coates is funded by an NIHR Clinician Scientist award. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. T.S. Jørgensen is on the speaker’s bureau for AbbVie, Roche, UCB, Novartis, and Biogen. L.C. Coates has received grant/research support from AbbVie, BMS, Celgene, Jannsen Pharmaceuticals, Lilly, MSD, Novartis, Pfizer, Sun Pharma, and UCB. A. Egeberg has received grant/research support from Pfizer and Eli Lilly, and is on the speaker’s bureau for Almirall, Samsung Bioepis Co., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. L. Dreyer is on the speaker’s bureau for MSD, UCB, and Janssen Pharmaceuticals. P. Højgaard is on the speaker’s bureau of Celgene, UCB, and J. Guldberg-Møller, and is a paid instructor for AbbVie. J. Merola has received grant/research support from Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, and is a consultant for Biogen IDEC, Eli Lilly, Novartis, Momenta, UCB, Kiniksa, AbbVie, Amgen, Pfizer, Janssen Pharmaceuticals, Momenta, and Mallinckrodt, and is on the speaker’s bureau for AbbVie. H. Gudbergsen is on the speaker’s bureau for MSD and Pfizer. L.E. Kristensen is on the speaker’s bureau of Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals.
M. Skougaard, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; S. Rifbjerg-Madsen, MD, PhD, The Parker Institute, and the Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte and Herlev; K. Amris, MD, DMsc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L. Dreyer, MD, Professor, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and the departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; P. Højgaard, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte and Herlev; J. Guldberg-Møller, MD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School; P. Frederiksen, MSc, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; H. Gudbergsen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg.
Address correspondence to Dr. L.E. Kristensen, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. E-mail: lars.erik.kristensen@regionh.dk.
Accepted for publication June 27, 2019.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study
Marie Skougaard, Tanja Schjødt Jørgensen, Signe Rifbjerg-Madsen, Laura C. Coates, Alexander Egeberg, Kirstine Amris, Lene Dreyer, Pil Højgaard, Jørgen Guldberg-Møller, Joseph F. Merola, Peder Frederiksen, Henrik Gudbergsen, Lars Erik Kristensen
The Journal of Rheumatology Jul 2019, jrheum.181412; DOI: 10.3899/jrheum.181412
Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study
Marie Skougaard, Tanja Schjødt Jørgensen, Signe Rifbjerg-Madsen, Laura C. Coates, Alexander Egeberg, Kirstine Amris, Lene Dreyer, Pil Højgaard, Jørgen Guldberg-Møller, Joseph F. Merola, Peder Frederiksen, Henrik Gudbergsen, Lars Erik Kristensen
The Journal of Rheumatology Jul 2019, jrheum.181412; DOI: 10.3899/jrheum.181412